HC Wainwright Brokers Boost Earnings Estimates for IOVA

Key Points

• HC Wainwright raised Iovance Biotherapeutics’ Q3 2026 EPS estimate to a loss of $0.09 from a previous forecasted loss of $0.12, while maintaining a “Buy” rating and $20 price target.
• Iovance lifted its 2026 revenue guidance to $410 million–$420 million, citing strong U.S. demand for Amtagvi and Proleukin; the revised outlook prompted several analysts to increase their price targets.
• IOVA opened at $14.82, near its 52-week high of $15.30, following a sharp rally. Analysts remain broadly positive, with nine Buy ratings and an average price target of $12.40, though some caution that the expected turnaround may already be reflected in the valuation.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Investment analysts at HC Wainwright increased their Q3 2026 earnings per share estimates for Iovance Biotherapeutics in a research note issued on Tuesday, September 29th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will post earnings per share of ($0.09) for the quarter, up from their previous estimate of ($0.12). HC Wainwright has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for Iovance Biotherapeutics' current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Iovance Biotherapeutics' Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.49) EPS and FY2027 earnings at ($0.24) EPS.

IOVA has been the topic of a number of other reports. Mizuho increased their price target on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an "outperform" rating in a report on Tuesday, August 18th. The Goldman Sachs Group began coverage on shares of Iovance Biotherapeutics in a report on Thursday, September 24th. They issued a "buy" rating and a $15.00 price objective for the company. UBS Group upped their price objective on shares of Iovance Biotherapeutics from $4.00 to $7.00 and gave the stock a "neutral" rating in a research report on Thursday, August 20th. Citigroup reissued an "outperform" rating on shares of Iovance Biotherapeutics in a research note on Friday, August 7th. Finally, Barclays raised their target price on Iovance Biotherapeutics from $13.00 to $15.00 and gave the company an "overweight" rating in a research report on Thursday, September 17th. Nine investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Iovance Biotherapeutics currently has an average rating of "Moderate Buy" and an average target price of $12.40.

Iovance Biotherapeutics Price Performance

NASDAQ:IOVA opened at $14.82 on Thursday. The company has a 50 day moving average price of $7.98 and a 200-day moving average price of $5.35. Iovance Biotherapeutics has a 1-year low of $1.76 and a 1-year high of $15.30. The firm has a market cap of $6.71 billion, a price-to-earnings ratio of -20.30 and a beta of 0.83.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.02. The business had revenue of $99.31 million for the quarter, compared to analyst estimates of $87.83 million. Iovance Biotherapeutics had a negative return on equity of 40.51% and a negative net margin of 89.11%.The business's quarterly revenue was up 65.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.33) EPS.

Institutional Investors Weigh In On Iovance Biotherapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. KBC Group NV purchased a new position in Iovance Biotherapeutics during the first quarter valued at $34,000. Sanctuary Advisors LLC purchased a new stake in shares of Iovance Biotherapeutics during the first quarter worth about $38,000. Fifth Third Bancorp acquired a new position in shares of Iovance Biotherapeutics during the 1st quarter worth about $39,000. Ceera Investments LLC acquired a new position in shares of Iovance Biotherapeutics during the 1st quarter worth about $44,000. Finally, First National Bank & Trust Co. of Newtown purchased a new position in Iovance Biotherapeutics in the 2nd quarter valued at about $51,000. Hedge funds and other institutional investors own 77.03% of the company's stock.

Key Iovance Biotherapeutics News

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance raised its 2026 total revenue guidance to $410 million-$420 million, up from the previous $350 million-$370 million range. The midpoint increase of $55 million exceeded consensus estimates of roughly $402 million and was attributed to strong U.S. demand for Amtagvi (lifileucel) and Proleukin. Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance
• Positive Sentiment: The upgraded outlook and strong melanoma-treatment demand drove heavy trading, with IOVA reaching its highest level in a year as investors reassessed the company’s revenue growth prospects. IOVA Stock Hits 52-Week High on Raised Revenue Outlook
• Positive Sentiment: Analysts raised their valuations following the guidance update. Wells Fargo lifted its price target to $18 from $14 and assigned an “overweight” rating, while HC Wainwright raised its target to $20 from $9 and maintained a “buy” rating. TD Cowen also issued a “buy” recommendation. Iovance Receives a Buy from TD Cowen
• Neutral Sentiment: The significant rally occurred on above-average volume, indicating strong investor interest, but momentum-focused coverage notes that recent earnings-estimate revisions may not support continued near-term gains.
• Negative Sentiment: One analysis downgraded Iovance to “hold,” arguing that the expected turnaround is increasingly reflected in the valuation after the surge. This creates a risk of profit-taking if future results do not continue to exceed the raised outlook. Iovance: The Turnaround Is Priced In

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a biotechnology company focused on developing and commercializing individualized cell therapies for patients with cancer. The company's platform uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient's tumor, expanded in a manufacturing facility and reinfused to help the immune system recognize and attack cancer cells.

Iovance's lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved by the U.S. Food and Drug Administration for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment with a PD-1-blocking antibody and, when applicable, a BRAF-targeted therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.